Exploring The Dynamic Landscape Of Digital Medicines And Digital Therapeutics

Disease diagnosis, treatment, management, and prevention are all common uses for digital health products. The introduction of digital medicines—and, more recently, digital therapeutics (DTx)—has begun to influence the treatment and management of certain diseases by consumers and clinicians.

As a result of the adoption of these new technologies and treatments, the regulatory and commercial environment for digital health products has been forced to evolve rapidly. The U.S. Food and Drug Administration (FDA) has issued various guidance documents, created initiatives such as the Software Precertification Pilot Program, and launched the Digital Health Center of Excellence. The agency is also working to identify opportunities to support and regulate these products with realistic expectations.

Driven by technological advances and increased acceptance of telehealth, see how digital medicines and DTx are poised to become an integral part of the healthcare model and how the industry prepares for it.